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Muscle-specific tyrosine kinase- (MuSK-) antibodies-positive Myasthenia Gravis accounts for about one third of Seronegative
Myasthenia Gravis and is clinically characterized by early onset of prominent bulbar, neck, shoulder girdle, and respiratory
weakness. The response to medical therapy is generally poor. Here we report a case of late-onset MuSK-antibodies-positive
Myasthenia Gravis presenting with signs of cognitive impairment and parkinsonism in addition to bulbar involvement and external
ophthalmoplegia. The pattern of involvement of both peripheral and central nervous system dysfunction might suggest a common
pathogenic mechanism, involving impaired cholinergic transmission.
1. Introduction
A generalized myasthenia gravis (MG) without detectable
anti-AChR antibodies, which is commonly referred to as
a seronegative Myasthenia Gravis (SNMG), is observed in
about 15% of patients with generalised MG [1]. In about one
third of these subjects IgG anti-Musk antibodies have been
detected with a significant female predominance and earlier
age at disease onset [2, 3]. Even though patients with anti-
MuSK-positive MG usually develop generalized weakness at,
or shortly after, onset, they display particular involvement
of bulbar and facial muscles and may present with isolated
neck, shoulder, or respiratory muscles weakness [4–6]. These
clinical features support the idea that the absence of anti-
AChR antibodies is not necessarily associated with a less se-
vere disease.
MuSK is a transmembrane polypeptide involved in phos-
phorylation, clustering [7], and diﬀerentiation of postsynap-
tic AChR at neuromuscular junction. The underlying disease
mechanism of anti-MuSK MG is still unclear. AChR levels
were found to be normal in these patients [8], and it has been
suggested that the presence of anti-MuSK antibodies may
result in neuromuscular transmission impairment [9] prob-
ably associated with reduced miniature endplate potential
amplitudes [10]. Here, we report a case of late-onset muscle-
specific tyrosine kinase (MuSK)-antibodies-positive Myas-
thenia Gravis (MG) with bulbar weakness, external oph-
thalmoplegia, parkinsonism and pathologic metabolic net-
work on cerebral FDG PET.
2. Case Report
A 73-years-old man was admitted to our hospital in
September 2008 for a rapidly progressive bulbar dysfunction
consisting of severe dysphagia, requiring a gastric tube place-
ment, dysarthria, nasal speech, and ophthalmoplegia with-
out ptosis. Over the past two years the patient experienced
similar episodes, often less severe, with a remitting-relapsing
course and spontaneous resolution within few days or weeks.
In the previous three months he was hospitalized twice for
severe dysphagia.
All investigations including AChR antibodies, autoim-
munity and inflammatory screening but also barium swallow
study, fibroscopy, and neck CT scan were normal. The
clinical response to steroid therapy (methylprednisolon 1 g/d
iv) for three days was inconsistent with a full recovery during
the first relapse and lack of clinical improvement on the
second relapse.
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At the age of 70 the patient developed asymmetrical,
progressive rest tremor in his legs. Cerebral MRI performed
at that time was normal. Thus, a diagnosis of atypical par-
kinsonism was made, and the patient was treated with le-
vodopa-carbidopa 100/25mg three times daily without sig-
nificant improvement.
He was referred to our centre for a further clinical eval-
uation. The neurological examination on admission showed
masked face with decreased eye blinking and astonished look.
Cranial nerve examination revealed external ophthalmople-
gia with partial downward gaze sparing without dyplopia,
weak forced eye closure, and severe lower cranial nerves in-
volvement with severe dysphagia, hypophonia, nasal speech,
and marked tongue weakness. Pharyngeal reflex was normal
and masseter reflex quite bright. Frontal release signs such
as glabellar, orbicularis oris, and palmomental reflexes were
present. Asymmetrical, prominently left-sided, rest tremor
was present distally in both legs. Strength was normal in the
four limbs, and osteotendineal reflexes were normal except
for areflexia in the left upper limb (previous trauma). Plantar
response was flexor. Axial rigidity was evident together with
gait disturbance characterized by tendency to turn “en bloc”
and freezing.
Biochemistry was normal including serum creatine
kinase. An increased level of serum lactate was detected
(2.5mmol, n.v. 0.7–2.1mmol), but this finding was not
confirmed by a second assay (0.9mmol). Antineuronal (Hu-
Yo-Ri) antibodies were absent. Anti-AChR antibodies and
voltage-gated calcium channel antibodies were also negative.
Chest CT scan, spirometry, and pulmonary assessment were
unremarkable.
Neurophysiological examination including complete
EMG/ENG of limbs and both low-rate repetitive nerve stim-
ulation (RNS) and single fibre EMG (SF-EMG) of the facial
nerve were normal. CSF examination was normal, including
CSF beta-amyloid and tau (total and phosphorylated) pro-
teins level determination.
Muscle biopsy of right biceps, collected after informed
consent, showed atrophy of both type I and type II muscle
fibres without abnormalities of COX and SDH reactions.
Cerebral MRI demonstrated slight temporal lobes atrophy
and aspecific small frontal white matter lesions (Figures
1(a)–1(d)). Cerebral FDG PET revealed a metabolic decrease
in the brainstem and medial temporal cortex (Figure 1(e)).
Neuropsychological examination revealed a mild subcortical
dementia with a predominant impairment of executive
functions consisting in reduced verbal fluency, in defective
planning and execution and constructive apraxia. Few days
after admission, the patient presented a progressive spon-
taneous clinical improvement and the gastric tube was re-
moved. He was treated with i.v methylprednisolon 1 g/d for
three days followed by oral steroid assumption (prednisolon
50mg/d) with tapering doses with mild benefit.
Two weeks later all laboratory tests were available, and
high titres of anti-MuSK (muscle-specific tyrosine kinase)
antibodies were found. Thus, a diagnosis of MuSK-Ab-pos-
itive MG was established and an immunosuppressive treat-
ment with Azathioprine 100mg was associated with pred-
nisolon 50mg/d. The 30-day clinical followup revealed a full
resolution of ophthalmoplegia and bulbar signs. Bradykine-
sia, freezing of gate, and axial rigidity remained unresponsive
to L-dopa treatment.
3. Discussion
Early onset of prominent bulbar, neck, shoulder girdle, and
respiratory weakness are the characteristic features of MuSK-
antibodies-positive Myasthenia Gravis. Our case presented
mild cognitive impairment and parkinsonism in association
with the typical bulbar involvement and external ophthal-
moplegia. A complete diagnostic workup including serum
lactate determination, muscle biopsy, CSF examination, and
cerebral MRI with DWI sequences excluded other diﬀer-
ential diagnosis including Lambert Eaton syndrome, mito-
chondrial disorders, chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP), motor neuron disease and
brainstem ischemia.
Despite the fact that predominant bulbar and cranial
involvement have been already described in MuSK-anti-
bodies-positive MG [5], the clinical course of our patient
was atypical. In fact, he presented with episodes of dyplopia
and dysphagia worsening progressively within few days and
spontaneously resolving, in absence of daily fluctuation or
fatigable weakness. To our knowledge, this is the first re-
port of MuSK-antibodies-positive MG associated to atyp-
ical parkinsonism and dysexecutive cognitive impairment.
Although cranial and bulbar signs are consistent with the
neuromuscular disorder, the levodopa-unresponsive parkin-
sonism with gait disturbance and the subcortical dementia
remained without a conclusive explanation. Parkinson’s dis-
ease was excluded for the absence of clinical criteria. The
cerebral MRI, showing only aspecific small frontal white
matter lesions, was not consistent with a vascular parkin-
sonism and a vascular cognitive impairment. An impaired
metabolism involving the brainstem evidenced by FDG PET
has been reported in PSP patients [11], but the clinical
course in this patient did not satisfy clinical criteria for PSP,
which require a gradually progressive course in addition to
supranuclear gaze palsy and postural instability with falls
[12].
Therefore, despite the lack of literature data on seroneg-
ative myasthenia, parkinsonism, and cognitive impairment,
it might be argued whether a common mechanism might
underlie the three diseases.
Cholinergic system has been involved in the pathogenesis
of movement disorders [13]. Cholinergic deficits are thought
to underline gait disturbance, and cognitive impairment in
PSP [14] as well as degeneration of cholinergic nuclei in the
mesopontine tegmentum has been described to influence
akinesia and gait initiation abnormalities in PD [15]. Finally,
a reduction in nicotinic receptors was reported in neurode-
generative diseases such as AD, DLB, and PD [16–18]. Anti-
Musk antibodies, other than in neuromuscular junction,
were detected in brain both in neurons and nonneuronal
tissues. Moreover, MuSK expression in the hippocampus
seems to play a critical role in memory retention [19]. Ac-
cording to this finding some patients aﬀected by MG were
observed to have memory deficits [20].
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Figure 1: Cerebral MRI axial PD/T2weighted (a, b) and coronal FLAIR (c, d) sequences showing small bilateral aspecific white matter lesions
(a, c) involving the frontal white matter (red arrows) and sparing the basal ganglia (b, d). (e) Axial and coronal cerebral FDG PET revealing
a metabolic decrease in the brainstem (pons and mesencephalon) and medial temporal cortex (red arrows).
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Since anti-MuSK antibodies have been recognized to
modulate AChR diﬀerentiation, phosphorylation, and clus-
tering, a common mechanism involving an antibody re-
sponse to nicotinic receptors and anti MuSK might explain
both the CNS and the muscular impairment [21]. Our hy-
pothesis is highly speculative, and further data provided
by experimental models and functional studies in humans
other than other case reports are necessary to support this
preliminary observation.
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